The U.S. Food and Drug Administration (FDA) has approved DORIBAX(TM) (doripenem for injection) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. DORIBAX has demonstrated activity against a wide range of Gram-positive and Gram-negative bacteria - including Pseudomonas -- that cause these serious infections.
According to the CDC, in the U.S., nearly 2 million people acquire bacterial infections in hospitals each year, 90,000 will die as a result. 70% of those infections are caused by pathogens resistant to at least one drug. In 1998, the total annual cost of antimicrobial resistance to U.S. society was at least $5 billion USD. Gram-negative infections quickly are becoming a top concern of doctors in the hospital setting.
Monday, October 15th, 2007 Tuesday, October 16th, 2007
1:30 PM - 1:45 PM ET 1:00 PM - 1:15 PM ET
Galaxy 25 Galaxy 26
Transponder 13 Transponder 24
Downlink Freq. 3960 Vertical Downlink Freq. 4180 Horizontal
Preview and access this video on Pathfire DMG: Slug # 28864
Search within the PR Newswire or MultiVu section by story ID # 28864 or by headline
For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail email@example.com
NEWS: New Anti-infective, DORIBAX, effective against a wide range of resistant gram-positive and gram-negative pathogens.
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/28864/consumer.html
* Joseph Solomkin, MD, Professor of Surgery and Director of Research,
University of Cincinnati College of Medicine
* Michael S. Niederman, MD, Chairman, Department of Medicine, Winthrop
* Pathogen Images
* Patient and Hospital Footage
* Product and Manufacturing Footage
VIDEO PROVIDED BY: Ortho-McNeil, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
|SOURCE Ortho-McNeil, Inc.|
Copyright©2007 PR Newswire.
All rights reserved